ArticleMaterials today. Bio2025
A tandem-unlocked cascade nanoreactor for high-contrast magnetic resonance imaging-guided enhanced ferroptosis-chemo synergistic therapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Emerging Nanoreactors for Precision Disease Treatment: From Principles to Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- pH-responsive CDs-based nanoplatform for chemo-resistant esophageal cancer treatment via downregulation of HIF-1α related pathway.Journal of nanobiotechnology · 2026Article
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis holds significant promise in cancer therapy due to its unique form of programmed cell death, marked by a strong ability to selectively target drug-resistant cells. However, therapeutic approaches leveraging ferroptosis face challenges associated with restricted efficacy, specificity, and unreliable imaging techniques for monitoring treatment progression. Herein, we design a sequential tandem-unlocked cascade nanoreactor (TPZ/HMOS/IO@GOx) for MRI-guided enhanced ferroptosis-chemo synergistic therapy. Specifically, within the tumor TME, GSH triggers the degradation of HMOS, leading to the release of GOx, IO, and TPZ from TPZ/HMOS/IO@GOx. The liberated GOx catalyzes the conversion of endogenous glucose, consuming O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.